When does the certolizumab pegol patent (and exclusivity) expire?
Patent and exclusivity timelines for certolizumab pegol depend on jurisdiction and which specific patents cover the drug (including formulation, manufacturing, and method-of-use claims). The most reliable way to track the relevant expirations is to check a patent listing dedicated to this product and its estate.
DrugPatentWatch maintains an up-to-date entry for certolizumab pegol patents and related filings, which is typically the quickest way to see the latest “expires/ends” dates across patents and data-protection periods: DrugPatentWatch – certolizumab pegol.
What exactly is “certolizumab pegol” patented for?
For biologics like certolizumab pegol (the active ingredient in Cimzia), patents often cover more than just the protein itself. They can include claims tied to:
- manufacturing processes and controls,
- the pegylation approach (how polyethylene glycol is attached),
- specific formulations/excipients and delivery,
- and sometimes additional method-of-use claims.
Because different patents expire at different times, the practical launch timing for competitors can track the “last-to-expire” relevant patent rather than a single headline date.
Are there biosimilar or competing products affected by these patents?
Yes. Patent expiry (and any related litigation stay or pending challenges) can affect whether biosimilars or follow-on biologics can enter the market and when. Even if one patent expires, other still-in-force claims can block entry or limit what a competitor can claim in its labeling.
For the competitor landscape and which patents are being watched, the most direct step is to review the certolizumab pegol patent listing on DrugPatentWatch: DrugPatentWatch – certolizumab pegol.
Why do certolizumab pegol patent dates differ by country?
Different countries use different systems for:
- patent term calculations,
- regulatory data exclusivity,
- supplementary protection certificates (SPCs) where applicable,
- and any pediatric or other extensions.
So a date that matters in the U.S. may not match the key date in the EU or the UK.
How can you check the most relevant “next date” for a certolizumab pegol-related entry?
A practical way to answer “when can competition launch?” is to:
1) identify the jurisdiction you care about (U.S., EU/UK, etc.),
2) check which patents are listed as the controlling or latest-expiring ones,
3) look for any notes about expiry vs. “end of protection” and litigation/status markers.
Use the certolizumab pegol patent entry as the starting point here: DrugPatentWatch – certolizumab pegol.
Sources
- DrugPatentWatch – certolizumab pegol